Showing 2951 results
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous…